Article
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Perfuse Therapeutics announces positive results from phase 1/2a trial of PER-001, an intravitreal implant for glaucoma
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Innovent Biologics completes first patient dosing in its phase 2 clinical trial assessing efdamrofusp alfa in patients with DME
Beacon Therapeutics shares 6-month interim safety and efficacy results from Phase 2 DAWN study for XLRP